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The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the orthorhombic
space group Pbca with the Fe2+ cation positioned on an inversion center. The
cyclopentadienyl (Cp) rings adopt an anti conformation in contrast with other
substituted ferrocenes in which the Cp rings appear in a nearly eclipsed
conformation. The Cp and the aromatic rings are positioned out of the plane,
with a twist angle of 70.20 (12), and the C(Cp)—C(CO) bond length is shorter
than a typical C—C single bond, which suggests a partial double-bond character
and delocalization with the Cp  system. The structure of the complex is
compared to other functionalized ferrocenes synthesized in our laboratory.
1. Chemical context
The gold standard of treatment for breast cancer has tradi-
tionally been cisplatin, a metal-based agent. Its administration,
alone or in combination with other drugs, is also highly
effective against various other types of cancers, including
ovarian, head and neck, bladder, testicular and lung cancers
(Galanski et al., 2005; Sandler et al., 2011). However, its clin-
ical use suffers from major drawbacks, such as severe toxic
side effects including neurotoxicity, hepatotoxicity, and
nephrotoxicity (Pabla & Dong, 2008), as well as a drug-resis-
tance phenomenon which leads to unsuccessful treatment
(Dempke et al., 2000). Consequently, other metal-based drugs
have been investigated, among them ferrocenes (Ko¨pf-Maier
et al., 1984). Ferrocene has the versatility of easy functionali-
zation providing a fertile field for structural modification and
to study structure–activity relationship (SAR).
Our group has been working in this field for many years,
leading to exciting and biologically active ferrocenes. A wide
variety of pendant (functional) groups have been attached or
linked to the Cp ring to tailor the anti-proliferative properties
of ferrocene, many of them with great success (Braga & Silva,
2013; Gasser et al., 2011; Jaouen & Metzler-Nolte, 2010; Fouda
et al., 2007; Jaouen, 2006; van Staveren & Metzler-Nolte, 2004;
Nguyen et al., 2009; Top et al., 2003; Vessie`res et al., 2005, 2006;
Mele´ndez, 2012; Vera et al., 2011, 2014). Lately, a new range of
organic chemotherapeutic compounds have been studied
using pyrrole derivatives. These pyrrole derivatives have
revealed good anti-proliferative activity and an increase in
membrane permeability, allowing the compounds to reach the
nucleus (Ghorab et al., 2014; Abou El Ella et al., 2008; Chat-
zopoulou et al., 2014; Mohamed et al., 2013; Hassan et al., 2009;
Esteves et al., 2010; Clark et al., 2007; Merighi et al., 2003).
Therefore, we functionalized ferrocene with a pyrrole, 4-(1H-
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pyrrol-1-yl)phenol, obtaining three new ferrocenes: 1,10-4-
(1H-pyrrol-1-yl)phenyl ferrocenedicarboxylate, 1,4-(1H-
pyrrol-1-yl)phenyl, 10-carboxyl ferrocenecarboxylate (Fc-
(CO2-Ph-4-Py)CO2H) and 4-(1H-pyrrol-1-yl)phenyl ferro-
ceneacetylate (Fc-CH2CO2-Ph-4-Py). We investigated their
biological activities on breast cancer cell line (MCF-7)
and among these ferrocenes, 1,10-4-(1H-pyrrol-1-yl)phenyl
ferrocenedicarboxylate (I) was shown to be most active in this
series (Pe´rez et al., 2015). Nevertheless, the solid-state struc-
ture of (I) has been elusive (Pe´rez et al., 2015). The importance
of this complex is the incorporation of pyrrole groups, which
are derivatives of biologically active compounds, as well as
pyrrole being an electrochemically active group precursor of
polymeric material. In addition, ferrocene anticancer activity
has been associated with its redox behavior and the capability
to produce reactive oxygen species (ROS) (Acevedo et al.,
2012; Kovjazin et al., 2003; Tabbi et al., 2002; Osella et al.,
2005). Thus, the attachment of an electrochemically active
group on ferrocene could potentiate the production of ROS
and enhance its anticancer activity.
Given that the solid-state structure of this complex is not
available, we determined the crystal structure of bis[4-(1H-
pyrrol-1-yl)phenyl] ferrocene-1,10-dicarboxylate, (I). Addi-
tionally, we compared the obtained crystal structure with other
functionalized ferrocenes synthesized in our laboratory viz.: 4-
bromophenyl (II) and 4-chlorophenyl ferrocenecarboxylate
(III) (Vera et al., 2014), and 1,10-methyl ferrocenedicarboxyl-
ate (IV) (Gao et al., 2009).
2. Structural commentary
The asymmetric unit contains one half-molecule since Fe2+ lies
on an inversion center, Fig. 1. This symmetry is implied by the
NMR data where only one set of signals were found for H2/H5
and H3/H4 of the Cp rings, as well as the H2/H6 and H3/H5 of
the phenyl and H2/H5 and H3/H4 of the pyrrole groups.
Consequently, the Cp rings adopt a perfect anti conformation.
The average Fe—C(Cp) bond length is 2.044 (10) A˚, which is
very similar to that reported for ferrocene (Dunitz et al., 1956)
and other structures previously reported by our lab (Vera et
al., 2014; Gao et al., 2009). The Fe—C bond length of the
substituted carbon [Fe—C1 2.032 (2) A˚] is shorter that the
remaining Fe—C bond lengths due to the inductive effect of
the carboxylate on the Cp ring. The twist angles between the
Cp ring and the carboxylate and the Cp ring and the aromatic
ring are 14.4 (3) (above the Cp plane) and 70.20 (12),
respectively.
To put it in perspective, we compare (I) with previously
synthesized ferrocenes in our group containing only one Cp
functionalized and a phenyl group attached to the carboxylate,
but with Br and Cl instead of pyrrole in the 4-position, (II) and
(III) (CCDC 949002 and 949003, Vera et al., 2014). First, in the
4-bromophenyl and 4-chlorophenyl derivatives, the Cp rings
are positioned in a nearly eclipsed conformation and parallel
with stagger angles < 3 and Cp tilt angles of 0.48–1.25. In
contrast, (I) has a perfect anti conformation. The carbonyl
carbon of (I) has a distorted trigonal–planar geometry,
analogous to the 4-chlorophenyl and 4-bromophenyl
ferrocenecarboxylates. The twist angles between the Cp ring
and the carboxylate for 4-bromo and 4-chlorophenyl
ferrocenecarboxylates (6.75–10.15) are smaller than that of
the subject complex, 14.4 (3). Additionally, as mentioned
previously, the carbonyl oxygen of (I) lies above the Cp plane
whereas for the bromo and chloro derivatives, the carbonyl
oxygens lie below the Cp plane. The twist angle between the
Cp and the aromatic ring is 70.20 (12) in (I), while in (II) and
(III) the two rings are positioned at higher angles, approaching
a perpendicular position.
The average Fe—C(Cp*) bond lengths of the substituted Cp
rings in the 4-bromo and 4-chlorophenyl derivatives are
identical, within experimental error, as in (I) [2.044 (13) A˚].
As mentioned before, the Fe—C bond length where the
pendant group is attached is substantially shorter than the
remaining Fe—C(Cp) distances. The same bonding pattern is
also observed for the 4-bromo and 4-chlorophenyl
ferrocenecarboxylates. The C(Cp)—C(CO) bond length in (I),
C1—C6, is shorter than a typical C—C single bond, [1.473 (3)
versus 1.54 A˚ (single bond); Pauling, 1960]. This suggests
partial double-bond character and delocalization with the Cp
 system in analogous manner to that for the 4-bromo and 4-
chloro derivatives.
In the structure of the disubstituted ferrocene Fe(C5H4-
CO2CH3)2, (IV) (Gao et al., 2009), the average Fe—C(Cp)
bond lengths are 2.048 (11)/2.049 (14) A˚, similar to the title
complex but the Cp rings adopt almost an eclipsed confor-
mation with a stagger angle of 2.37 (Fig. 2). In addition, the
functional groups are not positioned perfectly anti to each
other. The Fe—C(Cp)—C(CO) bond in (IV) [1.477 (4) A˚] is
notably shorter than a typical C—C single bond (1.54 A˚), in a
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Figure 1
The molecular structure of (I), with displacement ellipsoids drawn at the
30% probability level. Unlabelled atoms are related to labelled ones by
the symmetry operation x, y, z.
similar manner to the title complex, suggesting delocalization
with the Cp  system.
Finally, (I) contains two  ring systems, 4-(1H-pyrrol-1-
yl)phenyl, which in principle could be involved in intra-
molecular – or C—H   stacking similar to other 1,10-
disubstituted ferrocenes with an extended  ring system
(Okabe et al., 2009; Togni et al., 1994; Gelin & Thummel,
1992). However, such – or C—H   stacking is not
observed in (I) since the Cp rings adopt an anti conformation.
3. Synthesis and crystallization
The synthesis of (I) was accomplished by treating 1,10-
ferrocenedicarboxylic acid with oxalyl chloride according to
our recently published procedure (Pe´rez et al., 2015). 1H NMR
(500 MHz, CDCl3) ( p.p.m.): 7.37 (2H, d, ph;
3J = 8.8 Hz), 7.25
(2H, d, py; 3J = 2.8 Hz), 7.03 (2H, dd, ph; 3J = 1.3 Hz), 6.34 (2H,
dd, py; 3J = 1.6 Hz), 5.08 (2H, overlapping doublets, AA0, Cp),
4.64 (2H, overlapping doublets, BB0, Cp). 13CNMR (125 MHz,
CDCl3) ( p.p.m.): 169.0 (C O), 148.3, 138.6, 122.9, 121.5,
119.5, 110.5, 73.4, 72.4, 72.0. Analysis calculated for
C32H24O4FeN2: C, 69.05; H, 4.40; found: C, 68.62; H, 4.46.
Crystallization of (I) was performed inside an NMR tube
containing CD2Cl2 for a period of two weeks, obtaining block-
shaped orange crystals suitable for X-ray diffraction.
4. Refinement
Crystal data, data collection and structure refinement details
are summarized in Table 2. H atoms were positioned in
idealized locations (C(6)—H = 0.95, C(5)—H = 1.00 A˚ with
Uiso(H) = 1.2Ueq(C).
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Crystal system, space group Orthorhombic, Pbca
Temperature (K) 100
a, b, c (A˚) 10.6386 (15), 7.3948 (10),
30.554 (4)
V (A˚3) 2403.7 (6)
Z 4
Radiation type Mo K
 (mm1) 0.67
Crystal size (mm) 0.28  0.26  0.23
Data collection
Diffractometer Bruker APEXII CCD
Absorption correction Multi-scan (SADABS; Bruker,
2010)
Tmin, Tmax 0.833, 0.877
No. of measured, independent and






R[F 2 > 2(F 2)], wR(F 2), S 0.044, 0.117, 1.02
No. of reflections 2999
No. of parameters 178
H-atom treatment H-atom parameters constrained
	max, 	min (e A˚
3) 0.34, 0.62
Computer programs: APEX2 and SAINT (Bruker, 2010), SHELXS97 and SHELXTL
(Sheldrick, 2008) and SHELXL2013 (Sheldrick, 2015).
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Computing details 
Data collection: APEX2 (Bruker, 2010); cell refinement: SAINT (Bruker, 2010); data reduction: SAINT (Bruker, 2010); 
program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL2013 







a = 10.6386 (15) Å
b = 7.3948 (10) Å
c = 30.554 (4) Å
V = 2403.7 (6) Å3
Z = 4
F(000) = 1152
Dx = 1.537 Mg m−3
Mo Kα radiation, λ = 0.71073 Å
Cell parameters from 2807 reflections
θ = 2.7–28.1°
µ = 0.67 mm−1
T = 100 K
Block, orange
0.28 × 0.26 × 0.23 mm
Data collection 
Bruker APEXII CCD 
diffractometer
φ and ω scans
Absorption correction: multi-scan 
(SADABS; Bruker, 2010)
Tmin = 0.833, Tmax = 0.877
12444 measured reflections
2999 independent reflections
2247 reflections with I > 2σ(I)
Rint = 0.077













Hydrogen site location: inferred from 
neighbouring sites
H-atom parameters constrained
w = 1/[σ2(Fo2) + (0.047P)2 + 0.928P] 
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max < 0.001
Δρmax = 0.34 e Å−3
Δρmin = −0.62 e Å−3
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Special details 
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full 
covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and 
torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. 
An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq
Fe1 0.5000 0.5000 0.5000 0.01323 (14)
O1 0.23108 (15) 0.4748 (2) 0.41347 (5) 0.0213 (4)
O2 0.41465 (13) 0.3430 (2) 0.39352 (4) 0.0173 (3)
N1 0.37269 (16) 0.3889 (2) 0.21120 (5) 0.0133 (4)
C1 0.3680 (2) 0.3523 (3) 0.46783 (7) 0.0149 (4)
C2 0.3145 (2) 0.4294 (3) 0.50667 (6) 0.0169 (4)
H2A 0.2415 0.5142 0.5081 0.020*
C3 0.3857 (2) 0.3643 (3) 0.54286 (7) 0.0216 (5)
H3A 0.3716 0.3970 0.5742 0.026*
C4 0.4812 (2) 0.2469 (3) 0.52692 (7) 0.0191 (5)
H4A 0.5454 0.1827 0.5451 0.023*
C5 0.4712 (2) 0.2403 (3) 0.48035 (7) 0.0166 (4)
H5A 0.5262 0.1693 0.4601 0.020*
C6 0.3264 (2) 0.3975 (3) 0.42318 (6) 0.0144 (4)
C7 0.3923 (2) 0.3684 (3) 0.34853 (6) 0.0145 (4)
C8 0.48316 (19) 0.4601 (3) 0.32540 (7) 0.0155 (4)
H8A 0.5502 0.5182 0.3404 0.019*
C9 0.47630 (19) 0.4673 (3) 0.27993 (7) 0.0151 (4)
H9A 0.5398 0.5288 0.2639 0.018*
C10 0.37736 (19) 0.3853 (2) 0.25769 (6) 0.0121 (4)
C11 0.28353 (19) 0.2994 (3) 0.28206 (7) 0.0149 (4)
H11A 0.2137 0.2469 0.2674 0.018*
C12 0.29095 (19) 0.2899 (3) 0.32731 (6) 0.0154 (4)
H12A 0.2272 0.2302 0.3436 0.018*
C13 0.2795 (2) 0.3154 (3) 0.18518 (7) 0.0174 (4)
H13A 0.2077 0.2518 0.1954 0.021*
C14 0.3076 (2) 0.3494 (3) 0.14240 (7) 0.0195 (5)
H14A 0.2587 0.3153 0.1177 0.023*
C15 0.4232 (2) 0.4449 (3) 0.14143 (7) 0.0213 (5)
H15A 0.4661 0.4862 0.1161 0.026*
C16 0.4613 (2) 0.4663 (3) 0.18374 (7) 0.0184 (4)
H16A 0.5364 0.5248 0.1929 0.022*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
Fe1 0.0159 (2) 0.0111 (2) 0.0127 (2) −0.00228 (16) −0.00142 (16) 0.00108 (15)
O1 0.0196 (9) 0.0274 (8) 0.0169 (8) 0.0076 (7) −0.0004 (6) −0.0006 (6)
O2 0.0162 (8) 0.0220 (8) 0.0137 (7) 0.0029 (6) −0.0003 (6) −0.0013 (6)
supporting information
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N1 0.0123 (8) 0.0123 (8) 0.0154 (8) −0.0003 (7) 0.0015 (7) −0.0003 (6)
C1 0.0164 (10) 0.0125 (9) 0.0160 (10) −0.0039 (8) 0.0003 (8) −0.0003 (7)
C2 0.0161 (10) 0.0168 (10) 0.0179 (10) −0.0040 (9) 0.0031 (8) 0.0006 (8)
C3 0.0292 (12) 0.0190 (11) 0.0165 (11) −0.0081 (10) 0.0015 (9) 0.0016 (8)
C4 0.0232 (12) 0.0139 (10) 0.0201 (11) −0.0055 (9) −0.0051 (9) 0.0046 (8)
C5 0.0197 (11) 0.0105 (9) 0.0197 (11) −0.0009 (9) −0.0040 (9) 0.0007 (8)
C6 0.0149 (10) 0.0121 (9) 0.0162 (10) −0.0015 (8) 0.0004 (8) −0.0014 (7)
C7 0.0157 (10) 0.0137 (9) 0.0142 (10) 0.0024 (8) −0.0008 (8) −0.0014 (7)
C8 0.0135 (10) 0.0150 (10) 0.0180 (10) −0.0025 (8) −0.0008 (8) −0.0027 (8)
C9 0.0127 (10) 0.0135 (9) 0.0192 (10) −0.0006 (8) 0.0023 (8) 0.0003 (8)
C10 0.0127 (10) 0.0085 (9) 0.0151 (10) 0.0031 (8) 0.0003 (8) −0.0006 (7)
C11 0.0118 (10) 0.0136 (9) 0.0193 (10) −0.0027 (8) −0.0012 (8) 0.0004 (8)
C12 0.0150 (10) 0.0138 (9) 0.0173 (10) −0.0010 (8) 0.0023 (8) 0.0018 (8)
C13 0.0139 (10) 0.0163 (10) 0.0219 (11) −0.0002 (9) −0.0005 (8) −0.0016 (8)
C14 0.0211 (11) 0.0196 (11) 0.0177 (10) 0.0066 (9) −0.0016 (9) −0.0022 (8)
C15 0.0250 (13) 0.0211 (11) 0.0179 (11) 0.0031 (10) 0.0048 (9) 0.0015 (9)
C16 0.0161 (10) 0.0176 (10) 0.0217 (11) −0.0032 (9) 0.0035 (9) 0.0024 (8)
Geometric parameters (Å, º) 
Fe1—C1 2.032 (2) C3—H3A 1.0000
Fe1—C1i 2.033 (2) C4—C5 1.428 (3)
Fe1—C5 2.035 (2) C4—H4A 1.0000
Fe1—C5i 2.035 (2) C5—H5A 1.0000
Fe1—C3i 2.050 (2) C7—C8 1.376 (3)
Fe1—C3 2.050 (2) C7—C12 1.386 (3)
Fe1—C2 2.051 (2) C8—C9 1.392 (3)
Fe1—C2i 2.051 (2) C8—H8A 0.9500
Fe1—C4i 2.055 (2) C9—C10 1.392 (3)
Fe1—C4 2.055 (2) C9—H9A 0.9500
O1—C6 1.201 (3) C10—C11 1.398 (3)
O2—C6 1.366 (2) C11—C12 1.387 (3)
O2—C7 1.407 (2) C11—H11A 0.9500
N1—C13 1.382 (3) C12—H12A 0.9500
N1—C16 1.386 (3) C13—C14 1.364 (3)
N1—C10 1.422 (3) C13—H13A 0.9500
C1—C5 1.427 (3) C14—C15 1.418 (3)
C1—C2 1.434 (3) C14—H14A 0.9500
C1—C6 1.473 (3) C15—C16 1.364 (3)
C2—C3 1.424 (3) C15—H15A 0.9500
C2—H2A 1.0000 C16—H16A 0.9500
C3—C4 1.423 (3)
C1—Fe1—C1i 180.0 C3—C2—Fe1 69.63 (13)
C1—Fe1—C5 41.09 (8) C1—C2—Fe1 68.75 (12)
C1i—Fe1—C5 138.91 (8) C3—C2—H2A 126.3
C1—Fe1—C5i 138.91 (8) C1—C2—H2A 126.3
C1i—Fe1—C5i 41.09 (8) Fe1—C2—H2A 126.3
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C5—Fe1—C5i 180.0 C4—C3—C2 108.66 (19)
C1—Fe1—C3i 111.35 (8) C4—C3—Fe1 69.90 (12)
C1i—Fe1—C3i 68.66 (8) C2—C3—Fe1 69.74 (12)
C5—Fe1—C3i 111.27 (9) C4—C3—H3A 125.7
C5i—Fe1—C3i 68.73 (9) C2—C3—H3A 125.7
C1—Fe1—C3 68.65 (8) Fe1—C3—H3A 125.7
C1i—Fe1—C3 111.34 (8) C3—C4—C5 107.97 (18)
C5—Fe1—C3 68.73 (9) C3—C4—Fe1 69.54 (12)
C5i—Fe1—C3 111.27 (9) C5—C4—Fe1 68.84 (11)
C3i—Fe1—C3 180.0 C3—C4—H4A 126.0
C1—Fe1—C2 41.11 (8) C5—C4—H4A 126.0
C1i—Fe1—C2 138.89 (8) Fe1—C4—H4A 126.0
C5—Fe1—C2 69.15 (9) C1—C5—C4 107.75 (18)
C5i—Fe1—C2 110.85 (9) C1—C5—Fe1 69.36 (11)
C3i—Fe1—C2 139.37 (9) C4—C5—Fe1 70.30 (11)
C3—Fe1—C2 40.63 (9) C1—C5—H5A 126.1
C1—Fe1—C2i 138.89 (8) C4—C5—H5A 126.1
C1i—Fe1—C2i 41.11 (8) Fe1—C5—H5A 126.1
C5—Fe1—C2i 110.85 (9) O1—C6—O2 123.84 (18)
C5i—Fe1—C2i 69.15 (9) O1—C6—C1 126.17 (19)
C3i—Fe1—C2i 40.63 (9) O2—C6—C1 109.97 (18)
C3—Fe1—C2i 139.37 (9) C8—C7—C12 120.85 (19)
C2—Fe1—C2i 180.0 C8—C7—O2 116.66 (18)
C1—Fe1—C4i 111.29 (8) C12—C7—O2 122.16 (18)
C1i—Fe1—C4i 68.71 (8) C7—C8—C9 119.63 (19)
C5—Fe1—C4i 139.13 (9) C7—C8—H8A 120.2
C5i—Fe1—C4i 40.87 (9) C9—C8—H8A 120.2
C3i—Fe1—C4i 40.56 (9) C10—C9—C8 120.67 (19)
C3—Fe1—C4i 139.44 (9) C10—C9—H9A 119.7
C2—Fe1—C4i 111.44 (9) C8—C9—H9A 119.7
C2i—Fe1—C4i 68.56 (9) C9—C10—C11 118.55 (18)
C1—Fe1—C4 68.71 (8) C9—C10—N1 120.40 (18)
C1i—Fe1—C4 111.29 (8) C11—C10—N1 121.05 (17)
C5—Fe1—C4 40.87 (9) C12—C11—C10 120.90 (19)
C5i—Fe1—C4 139.13 (9) C12—C11—H11A 119.5
C3i—Fe1—C4 139.44 (9) C10—C11—H11A 119.5
C3—Fe1—C4 40.56 (9) C7—C12—C11 119.31 (19)
C2—Fe1—C4 68.56 (9) C7—C12—H12A 120.3
C2i—Fe1—C4 111.44 (9) C11—C12—H12A 120.3
C4i—Fe1—C4 180.00 (11) C14—C13—N1 108.78 (19)
C6—O2—C7 119.52 (16) C14—C13—H13A 125.6
C13—N1—C16 107.58 (17) N1—C13—H13A 125.6
C13—N1—C10 126.34 (17) C13—C14—C15 107.54 (19)
C16—N1—C10 126.08 (18) C13—C14—H14A 126.2
C5—C1—C2 108.28 (18) C15—C14—H14A 126.2
C5—C1—C6 127.65 (19) C16—C15—C14 107.2 (2)
C2—C1—C6 123.89 (19) C16—C15—H15A 126.4
C5—C1—Fe1 69.56 (12) C14—C15—H15A 126.4
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C2—C1—Fe1 70.14 (12) C15—C16—N1 108.9 (2)
C6—C1—Fe1 122.25 (14) C15—C16—H16A 125.6
C3—C2—C1 107.3 (2) N1—C16—H16A 125.6
Symmetry code: (i) −x+1, −y+1, −z+1.
